Related Experiment Videos
Considering Fas ligand as a target for therapy
Andreas Linkermann1, Jing Qian, Marcus Lettau
1Medical Center Schleswig-Holstein Campus Kiel, Institute of Immunology, Michaelisstr. 5, D-24105 Kiel, Germany.
Expert Opinion on Therapeutic Targets
|March 11, 2005
Summary
Fas ligand (FasL) is a key factor in cell death and immune responses. Its complex roles and forms, including soluble FasL (sFasL), present challenges and opportunities for therapeutic interventions.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Fas ligand (FasL) is a critical mediator of apoptosis and immune cell regulation.
- FasL plays dual roles in target cell lysis, immune privilege, and tumor survival.
- The complex expression and functions of FasL necessitate careful consideration for therapeutic applications.
Purpose of the Study:
- To review the multifaceted roles of FasL and its soluble form (sFasL).
- To explore the clinical and pharmacological potential of targeting the FasL/Fas system.
- To highlight the complexities and potential side effects of FasL-based therapies.
Main Methods:
- Literature review of FasL/Fas system biology.
- Analysis of FasL expression patterns and functions.
- Evaluation of soluble FasL (sFasL) as a potential biomarker.
Main Results:
- FasL exhibits complex inducible and constitutive expression patterns.
- FasL functions as both a death factor and a co-stimulatory molecule in lymphocytes.
- Increased sFasL levels are observed in various diseases, suggesting diagnostic potential.
Conclusions:
- The diverse functions and forms of FasL, including sFasL, offer therapeutic targets but also pose risks of side effects.
- Understanding the pathophysiology of sFasL is crucial for its use as a diagnostic marker.
- Further research into the FasL/Fas system is warranted for developing effective therapeutic strategies.